Workflow
广康生化(300804) - 300804广康生化投资者关系管理信息20250919

Group 1: Company Performance - The company achieved revenue and profit growth in the first half of the year despite challenges in the agricultural chemical industry, such as overcapacity and price pressure [2] - The company's production and sales of key products, such as Keguan Dan and Mie Jun Dan, have increased significantly, with the production capacity being fully utilized [2] - The company is actively advancing the expansion plan for Mie Jun Dan to meet the growing customer demand, which is expected to enhance its market share and competitiveness globally [2] Group 2: Market and Investor Relations - The recent decline in stock price and shareholder sell-offs are attributed to macroeconomic factors, industry cycles, and market sentiment, which are beyond the company's control [3] - The company emphasizes its commitment to maintaining market value and has disclosed a stock price stabilization plan in its prospectus, which will be executed if certain conditions are met [3] - The company reassures investors of its stable operational activities and strategic planning, expressing confidence in long-term growth and performance [3]